NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2018 and provides a business update. “We are steadfast in our belief that Avenova is the best topical product available to treat chronic bacterial infections that affect about 85% of those suffering from dry eye. We are affi

Full Story →